NDAORALCAPSULE
Approved
Nov 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CENTRAX (prazepam) is an oral benzodiazepine capsule approved by Pfizer in 1979 for anxiety disorders. The drug works by enhancing GABAergic neurotransmission in the central nervous system to reduce anxiety symptoms. Prazepam is a classic anxiolytic used in symptomatic management of generalized anxiety.
LOE Approaching
LOE-approaching lifecycle suggests downsizing commercial teams and shifting focus to managed decline or repositioning strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero current job openings linked to CENTRAX reflect its maturity and LOE-approaching status. Career opportunities on this product are limited and likely focused on managed decline, compliance, and transition planning rather than growth.
Brand ManagerField Sales Representative
Worked on CENTRAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.